Opinion on Pharmaceuticals

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA meeting 2009: clinical data support potential label expansions in GAD

In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: new schizophrenia products and depot formulations

The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: novel drugs face challenges in mature depression and bipolar markets

At the recent meeting of the American Psychiatric Association, Forest/Gedeon Richter and Lundbeck attracted attention following the presentation of positive data for two novel drugs in bipolar disorder and depression, respectively. Given that both these indications are highly competitive and genericized markets, the companies are already seeking to differentiate their respective products.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: Shire to maintain market leading status in ADHD

At the American Psychiatric Association's annual meeting, British pharmaceutical firm Shire presented data on its diverse attention deficit hyperactivity disorder portfolio, covering three key products. Through continued astute portfolio management, Datamonitor forecasts Shire to remain the market leader with a 40% share of the ADHD sector by 2017.

Published By Datamonitor
29 May 2009
CommentWire
CommentWire

Apotex: generic launch accelerates threat to Plavix

Apotex has launched 'at risk' its generic version of Plavix, delivering a blow to Bristol-Myers Squibb and Sanofi-Aventis' efforts to fend off generic competition. Apotex' bold move, along with the big pharma firms' willingness to settle over ongoing patent litigation, indicates there is a good chance the patent will be invalidated, casting serious doubt over the future of this key revenue stream.

Published By Datamonitor
10 Aug 2006
CommentWire
CommentWire

Applied Biosystems: developing a test for Alzheimer's disease

Applied Biosystems has announced results from a study to discover reliable biomarkers of Alzheimer's disease that bring hope for an effective diagnostic a step closer. Furthermore, the findings also have wider implications for the development of treatments to stop the progression of the disease.

Published By Datamonitor
25 Aug 2006
Expert View
Expert View

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

Published By Datamonitor
17 May 2010
Expert View
Expert View

APS 2010: opioid safety and tolerability analyses take center stage

Opioid-related announcements at this year's American Pain Society meeting reflected the FDA's current focus on instituting regulations to increase the safety of this class. Johnson & Johnson used the meeting to present long-term data for its advanced candidate tapentadol, while King Pharmaceuticals demonstrated a taper procedure to be successful in minimizing withdrawal in patients taking Embeda.

Published By Datamonitor
17 May 2010

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.